Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years

NCT01928472 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01928472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01928472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
Lead sponsor
Novartis Vaccines
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
September 30, 2014
Enrollment
402 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

h7n9 influenza